Oncodesign Precision MedicineFRA:ZR8 32 PB Ratio is 0.10 as of Jul. 12, 2026, which is 96% below its 10-year median of 2.69. GuruFocus rates FRA:ZR8 with a GF Score™ of 32/100 and a GF Value™ of €0.26 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, Oncodesign Precision Medicine ranks better than 99.35% on this metric.
Oncodesign Precision Medicine SA stock PB Ratio (=0.12) is close to 5-year low of 0.11.
The historical rank and industry rank for Oncodesign Precision Medicine's PB Ratio or its related term are showing as below:
FRA:ZR8'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 2.69 Max: 9.14
Current: 0.12
During the past 6 years, Oncodesign Precision Medicine's highest PB Ratio was 9.14. The lowest was 0.11. And the median was 2.69.
FRA:ZR8's PB Ratio is ranked better than 99.35% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:ZR8: 0.12
During the past 3 years, the average Book Value Per Share Growth Rate was 60.20% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncodesign Precision Medicine was 60.20% per year. The lowest was -39.80% per year. And the median was 10.20% per year.
Back to Basics: PB Ratio
Oncodesign Precision Medicine (FRA:ZR8) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oncodesign Precision Medicine PB Ratio Related Terms
Oncodesign Precision Medicine PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncodesign Precision Medicine's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncodesign Precision Medicine PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oncodesign Precision Medicine's PB Ratio falls into.
Oncodesign Precision Medicine PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oncodesign Precision Medicine (FRA:ZR8) has a PB Ratio of 0.10 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncodesign Precision Medicine and its competitors. This is 96% below median its historical median of 2.69. Over the past decade, Oncodesign Precision Medicine's PB Ratio has ranged from 0.11 to 9.14. According to the industry distribution chart, Oncodesign Precision Medicine ranks #8 out of 1231 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Oncodesign Precision Medicine's PB Ratio too high?
Oncodesign Precision Medicine's current PB Ratio of 0.10 is 96% below median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 9.14. The Biotechnology industry median PB Ratio is 2.93. Oncodesign Precision Medicine's value of 0.10 is 96.6% below this industry median. Based on the distribution chart, Oncodesign Precision Medicine ranks #8 out of 1231 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncodesign Precision Medicine has a GF Score™ of 32/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncodesign Precision Medicine ranks #8 out of 1231 companies for PB Ratio. This places Oncodesign Precision Medicine in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.93. Oncodesign Precision Medicine's value of 0.10 is 96.6% below this benchmark. Historically, Oncodesign Precision Medicine's own PB Ratio has ranged from 0.11 to 9.14 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 2.93, Oncodesign Precision Medicine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncodesign Precision Medicine's current PB Ratio of 0.10 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncodesign Precision Medicine and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncodesign Precision Medicine's current PB Ratio is 0.10, which is 96% below median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (FRA:ZR8) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.26, compared to a current price of €0.30 — trading 16.9% above its estimated fair value. The current PB Ratio is 0.10, which is 96% below median its 10-year median of 2.69 and 96.6% below the Biotechnology industry median of 2.93. Oncodesign Precision Medicine's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oncodesign Precision Medicine (FRA:ZR8), the current PB Ratio is 0.10 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?
Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued.
The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26.
GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.
Key valuation signals for FRA:ZR8:
PB Ratio: 0.10 (96% below median its 10-year median of 2.69)
GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
Industry Position: 96.6% below the Biotechnology median (#8 of 1231)
No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncodesign Precision Medicine Business Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score
Get the complete analysis for FRA:ZR8
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZR8 has been successfully added to your 
